New shot aims to tame hepatitis b without daily pills
NCT ID NCT07654283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop their daily medication. The study is open-label, meaning everyone knows they are getting the drug, and it is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-137 (an experimental drug given as a shot under the skin)
What this could lead to
If successful, this could point toward a new way to help people with chronic hepatitis B stop their daily antiviral pills and keep the virus under control.
What could go wrong
This is an early phase 2 trial with only 70 people, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B， CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Mangiagalli
Milan, 20122, Italy
-
Hôpital Beaujon
Clichy, 92118, France
-
King's College Hospital
London, SE5 9RS, United Kingdom
-
NYU Langone Health
New York, New York, 10016, United States
-
Stanford University
Palo Alto, California, 94304-1509, United States
-
Texas Liver Institute
San Antonio, Texas, 78215-2100, United States
-
University of Calgary
Calgary, Alberta, T2N 4N1, Canada
-
University of Maryland
Baltimore, Maryland, 21201-1009, United States
-
Vall d'Hebron Hospital
Barcelona, 8035, Spain